A stable isotope study reveals that CETP inhibitors significantly lower LP little A levels, with a notable 56% reduction at higher doses. Despite this promising result, the clinical implications for those with elevated LP little A remain uncertain. Genetic factors play a crucial role, as individuals with hypo functioning CETP tend to experience lower rates of heart disease and other chronic conditions.
